Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
Список исп. литературыСкрыть список 1. Azuma K, Uchiyama I, Katoh T et al. Prevalence and Characteristics of Chemical Intolerance: A Japanese Population-Based Study. Arch Environ Occup Health 2015; 70 (6): 341–53. 2. Barnes GP, Allen EH, Parker WA et al. Dental treatment needs among hospitalized adult mental patients. Spec Care Dent 1988; 8 (4): 173–7. 3. Bird AM, Smith TL, Walton AE. Current treatment strategies for clozapine-induced sialorrhea. Ann Pharmacother 2011; 45 (5): 667–75. 4. Bonnet U, Khalil-Boutros Y. Acute bilateral parotitis occurring during venlafaxine titration in an adolescent female with major depression. Pharmacopsychiatry 2014; 47 (1): 36–8. 5. Bosak M, Turaj W, Dudek D et al. Depressogenic medications and other risk factors for depression among Polish patients with epilepsy. Neuropsychiatr Dis Treat 2015; 11: 2509–17. 6. Brahm NC, Kelly-Rehm MC. Antidepressant-mediated gastroesophageal reflux disease. Consult Pharm 2011; 26 (4): 274–8. 7. Brown CS, Farmer RG, Soberman JE, Eichner SF. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmacokinet 2004; 43 (1): 33–56. 8. Carlone C, Rusconi AC, Valeriani G et al. Osteoporosis and major depression: open debate on a bidirectional relationship. [Article in Italian]. Riv Psichiatr 2015; 50 (4): 161–7. 9. Chisnoiu AM, Picos AM, Popa S et al. Factors involved in the etiology of temporomandibular disorders – a literature review. Clujul Med 2015; 88 (4): 473–8. 10. Christodoulou C, Margaritis D, Makris G et al. Quetiapine and clarithromycin-induced neuroleptic malignant syndrome. Clin Neuropharmacol 2015; 38 (1): 36–7. 11. Clark DB. Dental care for the patient with bipolar disorder. J Can Dent Assoc 2003; 69 (1): 20–4. 12. Cranford JA, Nolen-Hoeksema S, Zucker RA. Alcohol involvement as a function of co-occurring alcohol use disorders and major depressive episode: evidence from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2011; 117 (2–3): 145–51. 13. Da Silva AM, Newman HN, Oakley DA. Psychosocial factors in inflammatory periodontal diseases. A review. J Clin Periodontol 1995; 22: 516–26. 14. D'Mello DA. Are your patients depressed? Implications for dental practice. J Mich Dent Assoc 2003; 85 (5): 26–32. 15. Dost F, Do L, Farah CS. Knowledge of oral cancer risk factors amongst high risk Australians: findings from the "LESIONS" program. Aust Dent J 2016. 16. Essali A, Rihawi A, Altujjar M et al. Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. Cochrane Database Syst Rev 2013; 12: CD009546. 17. Falisi G, Rastelli C, Panti F et al. Psychotropic drugs and bruxism. Expert Opin Drug Saf 2014; 13 (10): 1319–26. 18. Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. Int J Psychiatry Med 2014; 48 (3): 185–97. 19. Friedlander AH, Friedlander IK. Dental management of the patient with major depressive disorder. Oral Health 2001; 91 (10): 47–57. 20. Friedlander AH, Friedlander IK, Gallas M, Velasco E. Late-life depression: its oral health significance. Int Dent J 2003; 53 (1): 41–50. 21. Friedlander AH, Friedlander IK, Yagiela JA, Eth S. Dental management of the child and adolescent with major depression. ASDC J Dent Child 1993; 60 (2): 125–31. 22. Friedlander AH, Kawakami KK, Ganzell S, Fitten LJ. Dental management of the geriatric patient with major depression. Spec Care Dentist 1993; 13 (6): 249–53. 23. Friedlander AH, Mahler ME. Major depressive disorder. Psychopathology, medical management and dental implications. J Am Dent Assoc 2001; 132 (5): 629–38. 24. Friedlander AH, Norman DC. Late-life depression: psychopathology, medical interventions, and dental implications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94 (4): 404–12. 25. Friedlander AH, West LJ. Dental management of the patient with major depression. Oral Surg Oral Mel Oral Pathol 1991; 71 (5): 573–8. 26. Gallego JA, Nielsen J, De Hert M et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012; 11 (4): 527–42. 27. Ganesh M, Hertzberg A, Nurko S et al. Acid Rather Than Nonacid Reflux Burden Is a Predictor of Tooth Erosion. J Pediatr Gastroenterol Nutr 2016; 62 (2): 309–13. 28. Georgellis A, Lindelöf B, Lundin A et al. Multiple chemical sensitivity in male painters; a controlled provocation study. Int J Hyg Environ Health 2003; 206 (6): 531–8. 29. Goodwin RD, Zvolensky MJ, Keyes KM, Hasin DS. Mental disorders and cigarette use among adults in the United States. Am J Addict 2012; 21 (5): 416–23. 30. Goulet JP, Pérusse R, Turcotte JY. Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions. Oral Surg Oral Med Oral Pathol 1992; 74 (5): 692–7. 31. Grohmann R, Ströbel C, Rüther E et al. Adverse psychic reactions to psychotropic drugs--a report from the AMUP study. Pharmacopsychiatry 1993; 26 (3): 84–93. 32. Gupta RK. Major depression: an illness with objective physical signs. World J Biol Psychiatry 2009; 10 (3): 196–201. 33. Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics, Part III in a series. J Am Dent Assoc 1999; 130 (3): 397–407. 34. Hausteiner C, Mergeay A, Bornschein S et al. New aspects of psychiatric morbidity in idiopathic environmental intolerances. J Occup Environ Med 2006; 48 (1): 76–82. 35. Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 2007; 29 (l): 2477–97. 36. Hock C, Drasch G, Golombowski S et al. Increased blood mercury levels in patients with Alzheimer's disease. J Neural Transm (Vienna) 1998; 105 (1): 59–68. 37. Jesus C, Jesus I, Agius M. What evidence is there to show which antipsychotics are more diabetogenic than others? Psychiatr Danub 2015; 27 (l): 423–8. 38. Józefowicz O, Rabe-Jabłońska J, Woźniacka A, Strzelecki D. Analysis of vitamin D status in major depression. J Psychiatr Pract 2014; 20 (5): 329–37. 39. Kahl KG, Greggersen W, Schweiger U et al. Prevalence of the metabolic syndrome in unipolar major depression. Eur Arch Psychiatry Clin Neurosci 2012; 262 (4): 313–20. 40. Kalkur C, Sattur AP, Guttal KS. Role of Depression, Anxiety and Stress in Patients with Oral Lichen Planus: A Pilot Study. Indian J Dermatol 2015; 60 (5): 445–9. 41. Kamolz T, Granderath FA, Pointner R. Does major depression in patients with gastroesophageal reflux disease affect the outcome of laparoscopic antireflux surgery? Surg Endosc 2003; 17 (1): 55–60. 42. Kuğu N, Akyüz G, Doğan O. Burning mouth syndrome and depression: a case report. (Article in Turkish). Turk Psikiyatri Derg 2002; 13 (3): 232–7. 43. Lampela P, Paajanen T, Hartikainen S, Huupponen R. Central Anticholinergic Adverse Effects and Their Measurement. Drugs Aging 2015; 32 (12): 963–74. 44. Laugharne J, Waterreus AJ, Castle DJ, Dragovic M. Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs. Australas Psychiatry 2015; pii: 1039856215618521. 45. Leonard BE. Pain, Depression and Inflammation: Are Interconnected Causative Factors Involved? Mod Trends Pharmacopsychiatry 2015; 30: 22–35. 46. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand Suppl 1994; 380: 8–13. 47. Little JW. Dental implications of mood disorders. Gen Dent 2004; 52 (5): 442–50. 48. Luca M, Luca A, Calandra C. Accelerated aging in major depression: the role of nitro-oxidative stress. Oxid Med Cell Longev 2013; 2013: 230797. 49. Luca M, Luca A, Grasso CM, Calandra C. Nothing to smile about. Neuropsychiatr Dis Treat 2014; 10: 1999–2008. 50. Mahatthanatrakul W, Sriwiriyajan S, Ridtitid W et al. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. J Clin Pharm Ther 2012; 37 (2): 221–5. 51. Malt UF, Nerdrum P, Oppedal B et al. Physical and mental problems attributed to dental amalgam fillings: a descriptive study of 99 self-referred patients compared with 272 controls. Psychosom Med 1997; 59 (1): 32–41. 52. Mohammed I, Nightingale P, Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: a community study. Aliment Pharmacol Ther 2005; 21 (7): 821–7. 53. Monteiro da Silva AM, Oakley DA, Newman HN et al. Psychosocial factors and adult onset rapidly progressive periodontitis. J Clin Periodontol 1996; 23: 789–94. 54. Morris AJ, Roche SA, Bentham P, Wright J. A dental risk management protocol for electroconvulsive therapy. J ECT 2002; 18 (2): 84–9. 55. Muraoka M, Mine K, Matsumoto K et al. Psychogenic vomiting: the relation between patterns of vomiting and psychiatric diagnoses. Gut 1990; 31 (5): 526–8. 56. Nakao M, Yamanaka G, Kuboki T. Major depression and somatic symptoms in a mind/body medicine clinic. Psychopathology 2001; 34 (5): 230–5. 57. Nielsen S. Benzodiazepines. Curr Top Behav Neurosci 2015. 58. Nordanskog P, Hultén M, Landén M et al. Electroconvulsive Therapy in Sweden 2013: Data From the National Quality Register for ECT. J ECT 2015; 31 (4): 263–7. 59. Olver IN. Xerostomia: a common adverse effect of drugs and radiation. Aust Prescr 2006; 29: 97–8. 60. Padala PR, Padala KP, Monga V et al. Reversal of SSRI-associated apathy syndrome by discontinuation of therapy. Ann Pharmacother 2012; 46 (3): 8. 61. Peeran SW, Kumar NP, Azaruk FA et al. Association between mental well-being, depression, and periodontal attachment level among young adults of the postwar Sebha city, Libya: A pilot study. J Nat Sci Biol Med 2014; 5 (2): 308–12. 62. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depressionsymptom profile. BMC Med 2013; 11: 129. 63. Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology (Berl) 2006; 185 (3): 265–73. 64. Raghavan SA, Puttaswamiah RN, Birur PN et al. Antidepressant-induced Burning Mouth Syndrome: A Unique Case. Korean J Pain 2014; 27 (3): 294–6. 65. Rogers DP, Shramko JK. Therapeutic options in the treatment of clozapine-induced sialorrhea. Pharmacotherapy 2000; 20 (9): 1092–5. 66. Ronsley R, Nguyen D, Davidson J et al. Panagiotopoulos C. Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. Can J Psychiatry 2015; 60 (10): 441–50. 67. Salerno C, Di Stasio D, Petruzzi M et al. An overview of burning mouth syndrome. Front Biosci (Elite Ed) 2016; 8: 213–8. 68. Saletu A, Pirker-Frühauf H, Saletu F et al. Controlled clinical and psychometric studies on the relation between periodontitis and depressive mood. J Clin Periodontol 2005; 32: 1219–25. 69. Sawchuk CN, Roy-Byrne P, Noonan C et al. The Association of Panic Disorder, Posttraumatic Stress Disorder, and Major Depression With Smoking in American Indians. Nicotine Tob Res 2015. 70. Sevrain M, Brenaut E, Le Toux G, Misery L. Primary Burning Mouth Syndrome: A Questionnaire Study of Neuropathic and Psychological Components. Am J Clin Dermatol 2015. 71. Sjogren R, Nordstrom G. Oral health status of psychiatric patients. J Clin Nurs 2000; 9 (4): 632–8. 72. Szafrański T. Neuroleptic induced deficit syndrome. (Article in Polish) Psychiatr Pol 1995; 29 (3): 359–69. 73. Talati A, Wickramaratne PJ, Keyes KM et al. Smoking and psychopathology increasingly associated in recent birth cohorts. Drug Alcohol Depend 2013; 133 (2): 724–32. 74. Van Soest EM, Dieleman JP, Kuipers E.J. The effect of anticholinergic agents on gastro-oesophageal reflux and related disorders. Expert Opin Drug Saf 2008; 7 (2): 173–80. 75. Velasco E, Bullon P. Periodontal status and treatment needs among Spanish hospitalized psychiatric patients. Spec Care Dentist 1999; 19 (6): 254–8. 76. Watts BV, Groft A, Bagian JP, Mills PD. An examination of mortality and other adverse events related to electroconvulsive therapy using a national adverse event report system. J ECT 2011; 27 (2): 105–8. 77. Weber B., Schweiger U, Deuschle M, Heuser I. Major depression and impaired glucose tolerance. Exp Clin Endocrinol Diabetes 2000; 108 (3): 187–90. 78. Yagiela JA. Adverse drug interactions in dental practice: interactions associated with vasoconstrictors. Part V of a series. J Am Dent Assoc 1999; 130 (5): 701–9.